ARK Genomic Revolution ETF
ARKG
470 hedge funds and large institutions have $1.75B invested in ARK Genomic Revolution ETF in 2021 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 176 increasing their positions, 152 reducing their positions, and 76 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 176 | Existing positions reduced: 152
0.19% less ownership
Funds ownership: 24.52% → 24.34% (-0.19%)
9% less funds holding
Funds holding: 514 → 470 (-44)
26% less capital invested
Capital invested by funds: $2.37B → $1.75B (-$627M)
46% less call options, than puts
Call options by funds: $224M | Put options by funds: $412M
51% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 76
53% less funds holding in top 10
Funds holding in top 10: 15 → 7 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$45.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$18.6M |
| 3 |
LPL Financial
San Diego,
California
|
+$14.8M |
| 4 |
Jane Street
New York
|
+$11.9M |
| 5 |
PI
PEAK6 Investments
Chicago,
Illinois
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SDH
Sloy Dahl & Holst
Vancouver,
Washington
|
-$119M |
| 2 |
Goldman Sachs
New York
|
-$48.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$39.9M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$20M |
| 5 |
HF
HRT Financial
New York
|
-$15.5M |
ARKG Hedge Fund Activity: Q3 2021 in Review
470 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2021, worth a combined $1.75B — down 26% from $2.37B a quarter earlier.
Sellers outnumbered buyers: 76 funds closed out of ARKG and 37 opened new positions — a net loss of 39 holders — while 152 trimmed existing stakes and 176 added.
The largest buyer was Morgan Stanley, adding an estimated $45.6M. The largest seller was Sloy Dahl & Holst, cutting an estimated $119M.
- 470 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2021, down from 514 in Q2 2021.
- Funds reported $1.75B of ARK Genomic Revolution ETF stock for Q3 2021, down 26% quarter-over-quarter.
- 37 funds opened new ARK Genomic Revolution ETF positions in Q3 2021 and 76 closed out, a net change of -39 holders.
- The largest ARK Genomic Revolution ETF buyer in Q3 2021 was Morgan Stanley, an estimated $45.6M added.
- The largest ARK Genomic Revolution ETF seller in Q3 2021 was Sloy Dahl & Holst, an estimated $119M sold.
Based on aggregated 13F filings for Q3 2021.